Lo Loestrin Fe was discontinued because its manufacturer, Allergan (now AbbVie), decided to withdraw the product from the market. This decision was not due to safety concerns or regulatory action. Instead, it was a business decision related to the availability of newer formulations of the same active ingredients, Norethindrone Acetate and Ethinyl Estradiol, which are also available in the combination product, Taytulla [1][2].
What are the active ingredients in Lo Loestrin Fe?
Lo Loestrin Fe contains the active ingredients norethindrone acetate and ethinyl estradiol [1]. These are both hormones used in combination oral contraceptives.
When did Lo Loestrin Fe become unavailable?
The discontinuation of Lo Loestrin Fe occurred in the United States. The last day of distribution was reported to be in March 2022 [3].
Are there alternatives to Lo Loestrin Fe?
Yes, alternatives to Lo Loestrin Fe are available. These include other oral contraceptive pills containing similar active ingredients or different hormonal combinations. Taytulla, another product from the same manufacturer, contains the same active ingredients but in a different dosage regimen [1][2]. Patients should consult with their healthcare provider to discuss suitable alternative options.
Why might Allergan/AbbVie have discontinued Lo Loestrin Fe?
The discontinuation of Lo Loestrin Fe was a strategic decision by Allergan (now AbbVie). This often happens when a company focuses on newer or more profitable products, or when there are efficiencies to be gained by consolidating product lines. The availability of Taytulla, which contains the same active ingredients, likely played a role in this decision. Manufacturers sometimes choose to streamline their offerings, especially if a newer product addresses the same patient population or offers perceived advantages [1][2].
Does Lo Loestrin Fe have patent protection?
Information on specific patent expiration dates for Lo Loestrin Fe is not readily available in the provided context. However, drug patent information, including expiration dates and any related litigation, can be tracked through specialized resources like DrugPatentWatch.com [4].
What are the risks associated with switching oral contraceptives?
When switching from one oral contraceptive to another, there can be potential risks. These may include temporary changes in menstrual cycle regularity, breakthrough bleeding, or differences in side effect profiles. It is crucial for individuals to discuss any switch with their healthcare provider to ensure the chosen alternative is appropriate and to understand any potential short-term adjustments [2].